Targeting Metalloproteins by Fragment-Based Lead Discovery

Chemical Biology and Drug Design

Volumn 78, Issue 2, 2011, Pages 211-223

  Johnson, Sherida ^a   Barile, Elisa ^a   Farina, Biancamaria ^a   Purves, Angela ^a   Wei, Jun ^a   Chen, Li Hsing ^a   Shiryaev, Sergey ^a   Zhang, Ziming ^a   Rodionova, Irina ^a   Agrawal, Arpita ^b   Cohen, Seth M ^b   Osterman, Andrei ^a   Strongin, Alex ^a   Pellecchia, Maurizio ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FBLD; Metal chelating fragments; Metalloproteins; ZBG

Indexed keywords

BOTULINUM TOXIN A; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 8; LEAD; MATRIX METALLOPROTEINASE 14; METAL ION; METALLOPROTEIN; STROMELYSIN;

ARTICLE; CONTROLLED STUDY; DRUG DEVELOPMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LETHAL GENE; METAL BINDING; MOLECULAR LIBRARY; PRIORITY JOURNAL;

ANIMALS; CELLS, CULTURED; COORDINATION COMPLEXES; DRUG DELIVERY SYSTEMS; INHIBITORY CONCENTRATION 50; METALLOPROTEINS; MICE; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; SMALL MOLECULE LIBRARIES; ZINC;

EID: 79960357036     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01136.x     Document Type: Article

References (59)

1. Erlanson D.A., McDowell R.S., O'Brien T. (2004) Fragment-based drug discovery. J Med Chem;47:3463-3482.
2. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science;274:1531-1534.
3. Carr R.A., Congreve M., Murray C.W., Rees D.C. (2005) Fragment-based lead discovery: leads by design. Drug Discov Today;10:987-992.
4. Siegal G., Ab E., Schultz J. (2007) Integration of fragment screening and library design. Drug Discov Today;12:1032-1039.
5. Hajduk P.J., Greer J. (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov;6:211-219.
6. Jhoti H., Cleasby A., Verdonk M., Williams G. (2007) Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol;11:485-493.
7. Pellecchia M., Bertini I., Cowburn D., Dalvit C., Giralt E., Jahnke W., James T.L., Homans S.W., Kessler H., Luchinat C., Meyer B., Oschkinat H., Peng J., Schwalbe H., Siegal G. (2008) Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov;7:738-745.
8. Bembenek S.D., Tounge B.A., Reynolds C.H. (2009) Ligand efficiency and fragment-based drug discovery. Drug Discov Today;14:278-283.
9. Hann M.M., Leach A.R., Harper G. (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci;41:856-864.
10. Schuffenhauer A., Ruedisser S., Marzinzik A.L., Jahnke W., Blommers M., Selzer P., Jacoby E. (2005) Library design for fragment based screening. Curr Top Med Chem;5:751-762.
11. Mestres J., Veeneman G.H. (2003) Identification of ''latent hits" in compound screening collections. J Med Chem;46:3441-3444.
12. Gribbon P., Sewing A. (2005) High-throughput drug discovery: what can we expect from HTS? Drug Discov Today;10:17-22.
13. Kuntz I.D., Chen K., Sharp K.A., Kollman P.A. (1999) The maximal affinity of ligands. Proc Natl Acad Sci U S A;96:9997-10002.
14. Fattori D., Squarcia A., Bartoli S. (2008) Fragment-based approach to drug lead discovery: overview and advances in various techniques. Drugs R D;9:217-227.
15. Hajduk P.J., Shuker S.B., Nettesheim D.G., Craig R., Augeri D.J., Betebenner D., Albert D.H., Guo Y., Meadows R.P., Xu L., Michaelides M., Davidsen S.K., Fesik S.W. (2002) NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. J Med Chem;45:5628-5639.
16. Wang J., Uttamchandani M., Li J., Hu M., Yao S.Q. (2006) Rapid assembly of matrix metalloprotease inhibitors using click chemistry. Org Lett;8:3821-3824.
17. Flipo M., Beghyn T., Charton J., Leroux V.A., Deprez B.P., Deprez-Poulain R.F. (2007) A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening. Bioorg Med Chem;15:63-76.
18. Sternson S.M., Wong J.C., Grozinger C.M., Schreiber S.L. (2001) Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett;3:4239-4242.
19. Price S., Osbourn S.E. (2005) Solid-phase synthesis of N-formylhydroxylamines (reverse/retro-hydroxamates). Org Lett;7:3761-3763.
20. Jacobsen F.E., Lewis J.A., Cohen S.M. (2007) The design of inhibitors for medicinally relevant metalloporteins. ChemMedChem;2:152-171.
21. Jacobsen F.E., Lewis J.A., Cohen S.M. (2006) A new role for old ligands: discerning chelators for zinc metalloproteinases. J Am Chem Soc;128:3156-3157.
22. Agrawal A., Johnson S.L., Jacobsen J.A., Miller M.T., Chen L.H., Pellecchia M., Cohen S.M. (2010) Chelator fragment libraries for targeting metalloproteinases. ChemMedChem;5:195-199.
23. Shoop W.L., Xiong Y., Wiltsie J., Woods A., Guo J., Pivnichny J.V., Felcetto T. et al. (2005) Anthrax lethal factor inhibition. Proc Natl Acad Sci U S A;102:7958-7963.
24. Bouchain G., Delorme D. (2003) Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation. Curr Med Chem;10:2359-2372.
25. Michaelides M.R., Dellaria J.F., Gong J., Holms J.H., Bouska J.J., Stacey J., Wada C.K. et al. (2001) Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors. Bioorg Med Chem Lett;11:1553-1556.
26. Curtin M., Glaser K. (2003) Histone deacetylase inhibitors: the abbott experience. Curr Med Chem;10:2373-2392.
27. Pikul S., Ohler N.E., Ciszewski G., Laufersweiler M.C., Almstead N.G., De B., Natchus M.G., Hsieh L.C., Janusz M.J., Peng S.X., Branch T.M., King S.L., Taiwo Y.O., Mieling G.E. (2001) Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. J Med Chem;44:2499-2502.
28. Attenni B., Ontoria J.M., Cruz J.C., Rowley M., Schultz-Fademrecht C., Steinkuhler C., Jones P. (2009) Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model. Bioorg Med Chem Lett;19:3081-3084.
29. Aranapakam V., Davis J.M., Grosu G.T., Baker J., Ellingboe J., Zask A., Levin J.I. et al. (2003) Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem;46:2376-2396.
30. Dhiman R.K., Schaeffer M.L., Bailey A.M., Testa C.A., Scherman H., Crick D.C. (2005) 1-Deoxy-D-xylulose 5-phosphate reductoisomerase (IspC) from Mycobacterium tuberculosis: towards understanding mycobacterial resistance to fosmidomycin. J Bacteriol;187:8395-8402.
31. Congreve M., Carr R., Murray C., Jhoti H. (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today;8:876-877.
32. Booher R.N., Kornfeld E.C., Smalstig E.B., Clemens J.A. (1987) Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists. J Med Chem;30:580-583.
33. Summers J.B., Mazdiyasni H., Holms J.H., Ratajczyk J.D., Dyer R.D., Carter G.W. (1987) Hydroxamic acid inhibitors of 5-lipoxygenase. J Med Chem;30:574-580.
34. Giacomelli G., Porcheddu A., Salaris M. (2003) Simple one-flask method for the preparation of hydroxamic acids. Org Lett;5:2715-2717.
35. Miller T.A., Witter D.J., Belvedere S. (2005) Thiophene and Benzothiophene Hydroxamic Acid Derivatives, A61K ed, Boston, MA: p 1-186.
36. Boge N., Kruger S., Schroder M., Meier C. (2007) A new short and effcieint synthetic route to C8-N-acetylarylamine 2″-deoxyguanosine phosphoramidites. Synthesis;24:3907-3914.
37. Corbett M.D., Corbett B.R. (1980) Reaction of nitroso aromatics with glyoxylic acid. A new path to hydroxamic acids. J Org Chem;45:2834-2839.
38. Scozzafava A., Supuran C.T. (2000) Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem;43:3677-3687.
39. Kim M., Kim J.Y., Song K., Kim J., Lee J. (2007) Convenient total synthesis of taranabant (MK-0364), a novel cannabinoid-1 receptor inverse agonist as an anti-obesity agent. Tetrahedron;63:12845-12852.
40. Levin J.I., Rush T.S.I., Lovering F., Hu Y., Li J., Li W., Wu J.J., Hotchandani R., Xiang J.S., Du X., Cole D.C., Tam S.Y. (2005) Preparation of Amino acid Biarylsulfonamides as Metalloproteinase Inhibitors. New York, USA: Wyeth; p. 119.
41. Johnson S.L., Chen L.H., Harbach R., Sabet M., Savinov A., Cotton N.J., Strongin A., Guiney D., Pellecchia M. (2008) Rhodanine derivatives as selective protease inhibitors against bacterial toxins. Chem Biol Drug Des;71:131-139.
42. Kuzuyama T., Takahashi S., Takagi M., Seto H. (2000) Characterization of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, an enzyme involved in isopentenyl diphosphate biosynthesis, and identification of its catalytic amino acid residues. J Biol Chem;275:19928-19932.
43. Kuzuyama T., Shimizu T., Takahashi S., Seto H. (1998) Fosmidomycin, a specific inhibitor of 1-dexoy-D-xylulose 5-phosphate reductoisomerase in teh nonmevaolnate pathway for terpenoid biosynthesis. Tetrahedron Lett;39:7913-7916.
44. Rainey G.J., Wigelsworth D.J., Ryan P.L., Scobie H.M., Collier R.J., Young J.A. (2005) Receptor-specific requirements for anthrax toxin delivery into cells. Proc Natl Acad Sci USA;102:13278-13283.
45. Kitagawa M., Ara T., Arifuzzaman M., Ioka-Nakamichi T., Inamoto E., Toyonaga H., Mori H. (2005) Complelte set of ORF clones of Escherichia coli ASOA library (a complete set of E. coli K-12 ORF archive): unique resources for biological reserach. DNA Res;12:291-299.
46. Yang C., Rodionov D.A., Rodionova I.A., Li X., Osterman A.L. (2008) Glycerate 2-kinase of Thermotoga maritima and genomic reconstruction of related metabolic pathways. J Bacteriol;190:1173-1182.
47. Johnson S.L., Chen L.H., Pellecchia M. (2007) A high-throughput screening approach to anthrax lethal factor inhibition. Bioorg Chem;35:306-312.
48. Schepetkin I.A., Khlebnikov A.I., Kirpotina L.N., Quinn M.T. (2006) Novel small molecule inhibitors of anthrax lethal factor identified by high-througput screening. J Med Chem;49:5232-5244.
49. Yan Y.L., Miller M.T., Cao Y., Cohen S.M. (2009) Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. Bioorg Med Chem Lett;19:1970-1976.
50. Agrawal A., de Oliveira C.A., Cheng Y., Jacobsen J.A., McCammon J.A., Cohen S.M. (2009) Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor. J Med Chem;52:1063-1074.
51. Agrawal A., Romero-Perez D., Jacobsen J.A., Villarreal F.J., Cohen S.M. (2008) Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem;3:812-820.
52. Chen Y., Shoichet B.K. (2009) Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol;5:358-364.
53. Johnson A.T., Jiao G.S., Kim S. (2008) Hydroxamic Acid Derivatives of Phenoxy-Acetic Acids an Analogs Useful as Therapuetic Agents for Treating Anthrax Poisoning. Alea, HI, USA: PanThera Biopharma, LLC.
54. Johnson S.L., Chen L.H., Barile E., Emdadi A., Sabet M., Yuan H., Wei J., Guiney D., Pellecchia M. (2009) Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors. Bioorg Med Chem;17:3352-3368.
55. Radichev I.A., Remacle A.G., Shiryaev S.A., Purves A.N., Johnson S.L., Pellecchia M., Strongin A.Y. (2010) Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase. J Biol Chem;285:16076-16086.
56. Butler A. (1998) Acquisition and utilization of transition metal ions by marine organisms. Science;281:207-210.
57. Jacobsen J.A., Fullagar J.L., Miller M.T., Cohen S.M. (2011) Identifying chelators for metalloprotein inhibitors using a fragment-based approach. J Med Chem;54:591-602.
58. Becattini B., Culmsee C., Leone M., Zhai D., Zhang X., Crowell K.J., Rega M.F., Landshamer S., Reed J.C., Plesnila N., Pellecchia M. (2006) Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid. Proc Natl Acad Sci U S A;103:12602-12606.
59. Siliphaivanh P., Harrington P., Witter D.J., Otte K., Tempest P., Kattar S., Kral A.M., Fleming J.C., Deshmukh S.V., Harsch A., Secrist P.J., Miller T.A. (2007) Design of novel histone deacetylase inhibitors. Bioorg Med Chem Lett;17:4619-4624.